“十二五”战略框架下新生物制品医保准入制度研究  

Study on Medicare Drug Catalogue Access System of New Biological Products under the "Twelfth Five-year Plan" Strategic

作　　者：丁锦希[1] 李晓婷[1] 李思函[1] 蒋蓉[1] 

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国药事》2012年第12期1304-1309,共6页Chinese Pharmaceutical Affairs

基　　金：国家社会科学基金创新药物研发科技投入与激励法律制度研究(编号10CFX055)

摘　　要：目的研究"十二五"发展战略框架下新生物制品医保准入的必要性及制度内涵,为完善我国医保药品目录设计机制、鼓励创新提供合理化建议。方法理论研究、定量分析与个案分析相结合。结果新生物制品医保准入的经济效益和社会效益显著,但在准入标准及准入程序上缺乏相应激励机制。结论鼓励新生物制品的医保准入,应适当降低准入门槛,开通"绿色通道"。Objective To study the necessity and connotation of Medicare Drug Directory Access System（i.e.MDD-Access System） under the ＂ Twelfth Five-year Plan＂ strategic framework,and to provide rationalized proposals for improvement of the medicare drug catalogue design mechanism and encouraging innovation.Methods Theoretical research,quantitative analysis and case study were used.Results The economic and social benefits of new biological products′MDD-Access are remarkable,but the corresponding incentive mechanism of access criteria and procedures are still lack.Conclusion New biological products′ MDD-Access should be encouraged which means we should appropriately reduce the access standard and open a ＂ green channel＂.

关 键 词：“十二五”规划 新生物制品 医保准入 

分 类 号：R95[医药卫生—药学]